Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
STW5 · 2 trials · 2 indications
The pain intensity is documented on a 10 cm visual analogue scale (VAS) scale
Area under the curve (AUC) of patients' assessment of gastrointestinal symptoms evaluated by daily visual analogue scale (VAS)
| Arm | Type | Description |
|---|---|---|
| STW5 | EXPERIMENTAL | 2/3 patients with irritable bowel syndrome will be randomized in this arm |
| Placebo | PLACEBO_COMPARATOR | 1/3 patients with irritable bowel syndrome will be randomized in this arm |
| STW5 (Iberogast®, BAY98-7411) | EXPERIMENTAL | The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals. |
| Name | Type | Description |
|---|---|---|
| STW5 (Iberogast, BAY98-7411) | DRUG | Applied orally over 28 days, 20 drops STW 5 three times daily |
| Placebo | DRUG | Applied orally over 28 days, 20 drops placebo three times daily |
| STW5 (Iberogast®, BAY98-7411) | DRUG | The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals. |
Inclusion Criteria: * Patients of either sex aged \>18 years * Patients meeting the Rome III irritable bowel syndrome (IBS) diagnostic criteria. IBS is defined as recurrent abdominal pain or discomfort at least 3 days/month in last 3 months (onset at least 6 months ago) associated with two or more ...
Top 5 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 1 | PHASE3 | Eluxadoline |
| Ardelyx, Inc. | ARDX | 2 | PHASE3 | Tenapanor |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Eli Lilly and Company | LLY | 2 | PHASE2 | LY3537031 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE2 | Camlipixant |
STW5 is an investigational small molecule developed by Bayer AG for functional gastrointestinal disorders and irritable bowel syndrome. It is also known as Iberogast and BAY98-7411. STW5 is currently in Phase 2 clinical development.
STW5 is being studied for functional gastrointestinal disorders and irritable bowel syndrome. Clinical trials have evaluated it in patients with heartburn and backward flow of stomach liquid into the esophagus, as well as in irritable bowel syndrome diagnosed by ROME III criteria.
STW5 is developed by Bayer AG, which trades under the ticker BAYRY. Bayer is responsible for the clinical development of STW5 for gastrointestinal indications.
STW5 is in Phase 2 clinical development. One completed Phase 2 trial and one completed Phase 3 trial have been conducted. STW5 is investigational and has not been approved by the FDA for any indication.
STW5 has been evaluated in two completed trials: NCT04059900, a Phase 2 study in patients with heartburn and backward flow of stomach liquid into the esophagus, and NCT01940848, a Phase 3 study in irritable bowel syndrome. Both trials were conducted in Germany.
Yes, STW5 is also known as Iberogast and BAY98-7411. These names refer to the same investigational compound developed by Bayer AG for functional gastrointestinal disorders and irritable bowel syndrome.